Broad therapeutic uses of atypical antipsychotic medications

Biological Psychiatry

Volumn 50, Issue 11, 2001, Pages 912-924

  Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Atypical antipsychotic medications; Behavior disturbance; Geropsychiatry; Mood disorder; Neuropsychiatry

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AFFECTIVE NEUROSIS; BEHAVIOR DISORDER; CONFERENCE PAPER; DEMENTIA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METABOLIC DISORDER; MOOD; NEUROPSYCHIATRY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CLOZAPINE; DEMENTIA; DIBENZOTHIAZEPINES; HUMANS; MOOD DISORDERS; PERSONALITY DISORDERS; PIRENZEPINE; RISPERIDONE;

EID: 0035668484     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01256-2     Document Type: Conference Paper

References (119)

1. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
2. Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy
3. Antipsychotic-induced weight gain: A comprehensive research synthesis
4. Risperidone in children with significant conduct problems and subaverage intellectual functioning
5. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
6. Olanzapine versus divalpraex sodium for the treatment of acute mania
7. Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up
8. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder
9. The role of typical and atypical antipsychotic medications in the management of agitation and aggression
10. Comprehensive disease management for schizophrenia
11. The evolving clinical profile of atypical antipsychotic medications
12. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder
13. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities
14. Antipsychotic medications and the elderly: Effects on cognition and implications for use
15. Clozapine for treatment-refractory mania
16. Tardive and withdrawal dyskinesia in autistic children: A prospective study
17. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder
18. The effect of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease
19. Management of treatment resistance in schizophrenia
20. Effectiveness of risperidone in Huntington chorea patients
21. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week, placebo-controlled trial
22. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis
23. The use of olanzapine for movement disorder in Huntington's disease: A first case report
24. Effects of clozapine on alcohol and drug use disorders among patients with schizophrenia
25. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs
26. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12-week open label extension in the PSYCLOPS trial
27. Quetiapine for l-dopa-induced psychosis in PD
28. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
29. Quetiapine for the treatment of dopamimetic psychosis in Parkinson's disease
30. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: Results of an open label pilot study
31. Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics
32. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and regression analysis
33. New treatments for bipolar disorder: The role of atypical neuroleptic agents
34. Long-term risperidone treatment in bipolar disorder: 6-month follow up
35. Ziprasidone in the acute treatment of mania: A double-blind, placebo controlled, randomized trial
36. Clozapine reduces violence and persistent aggression in schizophrenia
37. Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses
38. Quetiapine fumarate (Seroquelô): A new atypical antipsychotic
39. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note
40. Clozapine, diabetes melitilus, weight gain, and lipid abnormalities: A five year naturalistic study
41. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - A functional approach
42. Three-year follow-up of older schizophrenics: Extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio
43. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry
44. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder
45. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia
46. Risperidone in the treatment of affective illness and obsessive-compulsive disorder
47. Rarity of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly
48. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients
49. Management of psychotic aspects of Parkinson's disease
50. Long-term quetiapine treatment for psychosis in patients with Parkinson's disease who failed treatment with other atypical antipsychotics
51. Client satisfaction with quetiapine
52. Pharmacologic treatment of schizophrenia
53. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis
54. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
55. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
56. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: Implications for the treatment of schizophrenia
57. Antipsychotic medications in the treatment of mood disorders
58. Ziprasidone in the acute treatment of patients with schizoaffective disorder: Results from 2 double-blind, placebo-controlled, multicenter studies
59. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia
60. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders
61. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
62. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine
63. Remission of self-mutilation in a patient with borderline personality during risperidone therapy
64. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches
65. Use of risperidone in psychosis associated with Huntington's disease
66. Clinical experience with quetiapine in elderly patients with psychotic disorder
67. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: A prospective study
68. Risperidone in the treatment of schizophrenia
69. Seroquel does not elevate prolactin levels in adolescents with selected psychotic disorders
70. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder
71. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders
72. Olanzapine in treatment resistant bipolar disorder
73. The management of psychosis and HIV
74. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
75. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease
76. Quetiapine and risperidone in outpatients with psychotic disorders: Results of the QUEST trial
77. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression
78. Older patients with schizophrenia: Challenges in the coming decades
79. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease
80. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study
81. QTC interval abnormalities and psychotropic drug therapy in psychiatric patients
82. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
83. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds
84. Management of psychotic, treatment-resistant depression
85. Olanzapine response in psychotic depression
86. Risperidone and haloperidol in mood disorders
87. Medication treatment of bipolar disorder 2000. The expert consensus series
88. Quetiapine in neuroleptic-dependent mood disorders
89. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study
90. Long-term olanzapine therapy in the treatment of Bipolar I disorder: An open-label continuous phase study
91. Treatment of borderline personality disorder: Potential of the new antipsychotic medications
92. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia
93. Risperidol compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial
94. Treatment of bipolar mixed state with olanzapine
95. The study of olanzapine plus fluoxetine is treatment-resistant major depressive disorder without psychiatric features
96. Treatment of elderly institutionalized bipolar patients with clozapine
97. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo
98. Short-term effects of olanzapine in Huntington disease
99. Behavioural problems associated with dementia: The role of newer antipsychotics
100. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
101. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania
102. Risperidone in comorbid borderline personality disorder and dysthymia
103. Efficacy of quetiapine in Parkinson's patients with psychosis
104. Clinical improvement and tolerability is maintained long-term in elderly patients with psychotic disorders treated with quetiapine
105. In vivo 1231 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
106. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
107. Olanzapine acute and long term efficacy in bipolar I patients
108. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
109. Olanzapine versus placebo in the treatment of acute mania
110. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
111. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia
112. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
113. Treatment of nonpsychotic relatives of patients with schizophrenia: Four case studies
114. What makes an antipsychotic "atypical"? Conserving the definition
115. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia
116. Divalproex sodium vs. olanzapine for the treatment of mania in bipolar disorder
117. An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone